Arthritis Patents (Class 514/825)
-
Patent number: 5698195Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-.alpha. (TNF.alpha.) and are useful in vivo for diagnosis and therapy of a number of TNF.alpha.-mediated pathologies and conditions, including rheumatoid arthritis as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: October 18, 1994Date of Patent: December 16, 1997Assignees: New York University Medical Center, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 5686431Abstract: The present invention relates to methods for the prevention and/or treatment of pathological processes involving the induction of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular Weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.Type: GrantFiled: June 1, 1995Date of Patent: November 11, 1997Assignee: Yeda Research and Development Co., Ltd.Inventors: Irun R. Cohen, Ofer Lider, Rami Hershkoviz
-
Patent number: 5686496Abstract: The new compound of formula ##STR1## may be prepared by conventional methods and used therapeutically as an LTB.sub.4 -receptor antagonist.Type: GrantFiled: March 28, 1997Date of Patent: November 11, 1997Assignee: Boehringer Ingelheim KGInventors: Ralf Anderskewitz, Kurt Schromm, Ernst-Otto Renth, Franz Birke, Armin Fugner, Hubert Heuer, Christopher Meade
-
Patent number: 5683698Abstract: The invention describes an herbal formulation and its use for reducing/alleviating symptoms associated with rheumatoid arthritis, osteoarthritis and reactive arthritis and for reducing the production of proinflammatory cytokines. Foods and beverages containing the herbal formulation are also described.Type: GrantFiled: August 2, 1996Date of Patent: November 4, 1997Assignee: New England Deaconess HospitalInventors: Sambasiva R. Chavali, R. Armour Forse
-
Patent number: 5679338Abstract: Applicants' invention discloses therapeutic compositions and methods for treating articular cartilage breakdown associated with osteoarthritis and rheumatoid arthritis. The compositions comprise a therapeutically effective amount of IL-4 to reduce or inhibit breakdown of articular cartilage, optionally in the presence of a pharmaceutically acceptable carrier or excipient. Methods for treating articular cartilage breakdown comprise administering a therapeutically effective amount of IL-4 to reduce or inhibit breakdown of articular cartilage, optionally in the presence of a pharmaceutically acceptable carrier to a subject in need of such treatment. The invention also relates to compositions and methods for treating tumor metastases, periodontal disease, emphysema and osteoporosis.Type: GrantFiled: May 12, 1994Date of Patent: October 21, 1997Assignee: Osteoarthritis Science, Inc.Inventors: Li-an Yeh, Andrew J. Augustine, Adrian Sheldon
-
Patent number: 5679667Abstract: Aminoalcohols N-acyl derivatives useful in the prevention and in the treatment of mammalian pathologies induced by mast cell degranulation in consequence of peripheral nerve noxae.Type: GrantFiled: October 21, 1994Date of Patent: October 21, 1997Assignee: Lifegroup S.P.A.Inventors: Francesco Della Valle, Silvana Lorenzi, Federica Della Valle
-
Patent number: 5679344Abstract: A glucosamine-containing composition that includes an anti-inflammatory proteolytic enzyme composition to increase the rapidity of physiological availability of the glucosamine and the method of increasing such availability by the use of proteolytic enzymes.Type: GrantFiled: July 20, 1995Date of Patent: October 21, 1997Assignee: Susan K. WilliamsInventors: Susan K. Williams, Stanley A. Bynum
-
Patent number: 5674853Abstract: The present invention features saponin containing enteral formulations for treatment of infection and inflammation. These saponin containing formulations are particularly useful in conjunction with oils rich in .omega.3 polyunsaturated fatty acids such as fish oils and flax oil but also show benefits with .omega.6 rich oils such as borage oil, black currant seed oil, canola oil and rapeseed oil. These formulations may also contain a lignan from the sesamin family.Type: GrantFiled: March 7, 1995Date of Patent: October 7, 1997Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: R. Armour Forse, Sambasiva Chavali
-
Patent number: 5663180Abstract: A class of 1,2-diarylcyclopentenyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula III: ##STR1## wherein each of R.sup.1 and R.sup.2 is independently selected from alkyl, hydrido, hydroxyalkyl, halo, haloalkyl, alkoxycarbonyl and carboxyl; wherein R.sup.5 is selected from alkylsulfonyl, haloalkylsulfonyl and sulfamyl; and wherein B is phenyl or pyridyl, wherein B is optionally substituted at a substitutable position with alkyl, halo, alkylthio, cyano, haloalkyl, alkoxy, hydroxyalkyl and alkoxyalkyl; or a pharmaceutically-acceptable salt thereof.Type: GrantFiled: July 15, 1994Date of Patent: September 2, 1997Assignee: G.D. Searle & Co.Inventors: David B. Reitz, Jinglin Li
-
Patent number: 5660830Abstract: Counter-irritants produce a slight irritation, as on an area of the skin, in order to relieve more serious inflammation elsewhere. Peppers, members of the Capsicum species, are a source of counter-irritants. The Scoville rating for a pepper provides a measure of the counter-irritant content of a given pepper. This invention provides for the solubilizing and recovery of the counter-irritants contained within peppers, having Scoville ratings of from 30,000 to 250,000, in the common capsaicin containing ethyl alcohol extract from the same specific peppers. The synergisitic pain relieving benefits of the counter-irritants in combination with the capsaicin provides superior pain relief for many hours after an application.Type: GrantFiled: September 14, 1994Date of Patent: August 26, 1997Inventor: Cleve Richard Anderson
-
Patent number: 5658949Abstract: A novel method of inhibiting production of two important mediators of cellular function, tumor necrosis factor and nitric oxide, and treating a pathophysiological state characterized by an undesirable production or level of tumor necrosis factor or nitric acid. The methods of the present invention employ retinoic acid compounds. The most preferred retinoic acid is all-trans-retinoic acid. Also provided is a method of inhibiting tumor necrosis factor receptors using retinoic acid-like compounds.Type: GrantFiled: November 30, 1994Date of Patent: August 19, 1997Assignee: Research Development FoundationInventor: Bharat B. Aggarwal
-
Patent number: 5651993Abstract: Methods and pharmaceutical compositions for modifying the immune response of a mammal to a specific antigen are provided. The methods include treating an antigen presenting cell to enhance expression of a major histocompatibility complex molecule and reacting the treated antigen presenting cell with the antigen extracorporeally to form an antigen-associated antigen presenting cell.Type: GrantFiled: November 18, 1992Date of Patent: July 29, 1997Assignee: Yale UniversityInventors: Richard L. Edelson, Francis P. Gasparro, Robert E. Tigelaar
-
Patent number: 5648373Abstract: Coenzyme A-independent transacylase is required for the release of free arachidonic acid, and the production of arachidonic acid metabolites and platelet activation factor. Blocking of this enzyme inhibits the production of these inflammatory mediators and will be of therapeutic utility in a broad range of allergic and inflammatory diseases and disorders. Compounds are described herein which inhibit the action of CoA-IT and are therefore useful in the treatment of disease states caused thereby.Type: GrantFiled: August 6, 1993Date of Patent: July 15, 1997Assignees: SmithKline Beecham Corporation, The Johns Hopkins UniversityInventors: James David Winkler, Floyd Harold Chilton, III, Deirdre Mary Bernadette Hickey
-
Patent number: 5648385Abstract: The present invention relates to a compound of formula ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in whichX is --O--CO--, --NH--CO--, --CS--NH--, --CO--O--, --CO--NH--, --COS--, --SCO--, --SCH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --C.tbd.C--, --CH.sub.2 --NH--, --COCH.sub.2 --, --NHCS--, --CH.sub.2 S--, --CH.sub.2 O--, --OCH.sub.2 --, --NHCH.sub.2 -- or --CR.sup.5 .dbd.CR.sup.6 --;R.sup.m and R.sup.k are independently hydrogen, halogen, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkyloxy or nitro;n is zero or one;R.sup.4 is --(CH.sub.2).sub.t --Y, C.sub.1-6 alkyl, or C.sub.3-6 cycloalkyl;R.sup.1 is --CO.sub.2 Z, C.sub.1-6 alkyl, CH.sub.2 OH, --CONHR.sup.y, or CHO;R.sup.2 and R.sup.3 are independently hydrogen or C.sub.1-6 alkyl;R.sup.a and R.sup.b are independently hydrogen or C.sub.1-6 alkyl; but when n is one, R.sup.a and R.sup.Type: GrantFiled: June 5, 1995Date of Patent: July 15, 1997Assignee: Bristol-Myers Squibb Co.Inventors: John E. Starrett, Jr., Kuo-Long Yu, Muzammil M. Mansuri, David R. Tortolani, Peter R. Reczek
-
Patent number: 5645820Abstract: Disclosed herein is a method for treating autoimmune diseases in mammals by administration of one or more agents selected from the group consisting of autoantigens specific for the autoimmune disease, disease-suppressive fragments and analogs of said autoantigen in aerosol form.Type: GrantFiled: April 10, 1995Date of Patent: July 8, 1997Assignee: AutoImmune, Inc.Inventors: David Allen Hafler, Howard L. Weiner
-
Patent number: 5646128Abstract: Novel compounds which selectively inhibit adenosine kinase and methods of preparing adenosine kinase inhibitors are provided. Also provided are methods of treating various inflammatory conditions, including arthritis and SIRS, which may be ameliorated by increased local concentrations of adenosine using adenosine kinase inhibitors.Type: GrantFiled: December 1, 1994Date of Patent: July 8, 1997Assignee: Gensia, Inc.Inventors: Gary S. Firestein, Bheemarao G. Ugarkar, Leonard P. Miller, Harry E. Gruber, David A. Bullough, Mark D. Erion, Angelo J. Castellino, Clinton E. Browne
-
Patent number: 5646152Abstract: Compounds of the formula ##STR1## wherein B, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined herein with reference to formula IX have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of panics, phobias and other stress-related disorders.Type: GrantFiled: June 15, 1994Date of Patent: July 8, 1997Assignee: Pfizer Inc.Inventors: Gene M. Bright, Yuhpyng L. Chen, Willard M. Welch
-
Patent number: 5645851Abstract: This invention provides a composition useful as an edible supplement for alleviating the symptoms of arthritis for oral consumption by mammals, said composition comprising animal tissue containing water-insoluble Type II collagen, which has been separated from non-Type II collagen containing tissue and has been sterilized in subdivided form without changing the original structure of the Type II collagen.Type: GrantFiled: April 9, 1996Date of Patent: July 8, 1997Inventor: Eugene R. Moore
-
Patent number: 5641473Abstract: Disclosed herein is a method for treating autoimmune diseases in mammals by administration of one or more agents selected from the group consisting of autoantigens specific for the autoimmune disease, disease-suppressive fragments and analogs of said autoantigen in aerosol form.Type: GrantFiled: June 6, 1995Date of Patent: June 24, 1997Assignee: AutoImmune, Inc.Inventors: David Allen Hafler, Howard L. Weiner
-
Patent number: 5641474Abstract: Disclosed herein is a method for treating autoimmune diseases in mammals by administration of one or more agents selected from the group consisting of autoantigens specific for the autoimmune disease, disease-suppressive fragments and analogs of said autoantigen in aerosol form.Type: GrantFiled: June 7, 1995Date of Patent: June 24, 1997Assignee: AutoImmune, Inc.Inventors: David Allen Hafler, Howard L. Weiner
-
Patent number: 5637321Abstract: This invention provides a method of preparing animal tissue containing water-insoluble undenatured Type II collagen for use in treating autoimmune arthritis, particularly rheumatoid arthritis.Type: GrantFiled: April 9, 1996Date of Patent: June 10, 1997Inventor: Eugene R. Moore
-
Patent number: 5633284Abstract: Dermatological compositions comprising nitrous oxide and at least one essential fatty acid or lower alkyl ester thereof in a dermatologically acceptable carrier medium is useful in the treatment of a variety of skin, muscle and joint disorders including psoriasis, shingles, fever blisters, chicken pox, ache, chilblains, eczema, chloasmas, alopecia, dermatitis, ringworm and burn wounds. The composition preferably also includes additional ingredients selected from coal tar, collagen, nicotinamide, nicotinic acid, lanolin, vitamin E, methyl salicylate, arnica, and H.sub.1 -antagonist antihistamines or combinations thereof.Type: GrantFiled: February 13, 1995Date of Patent: May 27, 1997Assignee: Pitmy International N.V.Inventor: Petrus J. Meyer
-
Patent number: 5624938Abstract: This invention provides a pharmaceutical composition which comprises an amount of chloroquine effective to block MHC Class I recycling and an amount of a CD8+ T cell stimulatory agent effective to stimulate proliferation of CD8+ T cells to a concentration such that the resulting CD8+ T cells kill CD4+ T cells, and a pharmaceutically acceptable carrier.This invention provides a method for treating an autoimmune disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the autoimmune disease.This invention provides a method for treating cutaneous lymphoma disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the cutaneous lymphoma disease.This invention provides a method for treating rheumatoid arthritis in a subject which comprises administering to the subject an amount of the pharmaceutical composition of chloroquine and a CD8+ T cell stimulatory agent effective to treat rheumatoid arthritis.Type: GrantFiled: July 18, 1994Date of Patent: April 29, 1997Assignee: The Trustees of Columbia University in the City of New YorkInventor: Benvenuto G. Pernis
-
Patent number: 5621009Abstract: A chondroprotective agent comprising a carboxylic acid compound of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are, independently, a hydrogen atom or an alkyl group of 1 to 6 carbon atoms, or a cis- or trans-isomer thereof, or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier is disclosed. The above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to protect cartilage, and thus, is extremely effective for the treatment of arthropathy.Type: GrantFiled: September 28, 1995Date of Patent: April 15, 1997Assignee: Kureha Chemical Industry Co., Ltd.Inventors: Koju Watanabe, Koichi Niimura, Kiyonori Umekawa
-
Patent number: 5616324Abstract: A synergistic mixture particularly suitable for the treatment of animals whic consists of at least two of the group consisting of DL.Phenylalanine, Ruta Graveolans and Corydali Bulbosa together with a carrier to make up a required volume, the mixture having a pro-inflammatory effect which accelerates the healing process of inflammation. It is preferred that there is provided mixture of DL.Phenylalanine with one product selected from the group of Ruta Graveolans and Corydalis Bulbosa. In a specific form, the mixture also includes Nicotinic Acid.Type: GrantFiled: May 31, 1995Date of Patent: April 1, 1997Inventors: Antoinette Foster, Don Foster
-
Patent number: 5616458Abstract: The present invention provides for the use of Tripterygium wilfordii Hook F extracts and purified components thereof in the treatment of inflammation or an immune disorder with concomitant lack of steroidal effect. Extracts of this plant (T2) bound to the glucocorticoid receptor and competitively inhibited glucocorticoid mediated cellular processes, such as dexamethasone binding to the glucocorticoid receptor, glucocorticoid mediated activation of target genes, dexamethasone dependent cellular growth, with concomitant inhibition of cyclooxygenase-2 induction and inflammatory processes such as the production of prostaglandin E.sub.2. The T2 extract components triptolide and tripdiolide were effective inhibitors. The particular advantage provided by the methods herein is the treatment or prevention of inflammation and the concomitant lack of steroidal agonist effects and NSAID side effects. Conditions treatable by the present methods include inflammation and immune disorders including autoimmune disease.Type: GrantFiled: May 31, 1995Date of Patent: April 1, 1997Assignee: Board of Regents, University of TX SystemInventors: Peter E. Lipsky, Xue-Lian Tao, Jian Cai, William J. Kovacs, Nancy J. Olsen
-
Patent number: 5605690Abstract: A method for treating TNF-dependent inflammatory diseases in a mammal by administering a TNF antagonist, such as soluble TNFR.Type: GrantFiled: February 8, 1995Date of Patent: February 25, 1997Assignee: Immunex CorporationInventors: Cindy A. Jacobs, Craig A. Smith
-
Patent number: 5593990Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.Type: GrantFiled: January 13, 1995Date of Patent: January 14, 1997Assignee: The Children's Medical Center CorporationInventor: Robert D'Amato
-
Patent number: 5587395Abstract: The present invention provides a complex compound having the structure: ##STR1## wherein R.sub.1 and R.sub.1' are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;wherein R.sub.2 and R.sub.2' are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3' are the same or different and each is hydrogen or an alkyl group;wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; andQ is a soluble, pharmaceutically acceptable negative ion.The invention also provides a method of treating a subject having a condition associated with the presence of free radicals in quantities sufficient to cause undesirable symptoms.Type: GrantFiled: April 25, 1995Date of Patent: December 24, 1996Assignee: Chai-Tech CorporationInventors: Zvi Dori, David Gershon
-
Patent number: 5578593Abstract: There are disclosed certain novel compounds identified as spiro piperidines and homologs which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such spiro compounds as the active ingredient thereof are also disclosed.Type: GrantFiled: November 3, 1993Date of Patent: November 26, 1996Assignee: Merck & Co., Inc.Inventors: Meng-Hsin Chen, David B. R. Johnston, Ravi P. Nargund, Arthur A. Patchett, James R. Tata, Lihu Yang
-
Patent number: 5576330Abstract: The new use of a compound of formula (I) ##STR1## wherein Y is a bicyclic ring selected from naphthalene, tetralin, quinoline, isoquinoline and indole;n is zero or an integer of 1 to 3;R.sub.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl;R.sub.2 is hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, cyano, carboxy, nitro, or NHR, wherein R is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.3 is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.4 is hydrogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, C.sub.2 -C.sub.6 alkanoyloxy, carboxy, nitro or NHR, wherein R is as defined above;R.sub.5 is hydrogen, C.sub.1 -C.sub.6 alkyl or halogen; or a pharmaceutically acceptable salt thereof;and wherein when Y is naphthalene then n is zero or an integer of 1 to 3, whereas when Y is tetralin, quinoline, isoquinoline or indole then n is zero, 1 or 2; and wherein when the bicyclic ring Y is naphthalene, quinoline, isoquinoline or indole, then each of the substituents OR.sub.1, R.sub.Type: GrantFiled: December 12, 1994Date of Patent: November 19, 1996Assignee: Farmitalia Carlo Erba S.r.l.Inventors: Franco Buzzetti, Antonio Longo, Maria G. Brasca, Fabrizio Orzi, Angelo Crugnola, Dario Ballinari, Mariangela Mariani
-
Patent number: 5571499Abstract: Disclosed herein is a method for treating autoimmune diseases in mammals by administration of one or more agents selected from the group consisting of autoantigens specific for the autoimmune disease, disease-suppressive fragments and analogs of said autoantigen in aerosol form.Type: GrantFiled: June 6, 1995Date of Patent: November 5, 1996Assignee: Autoimmune, Inc.Inventors: David A. Hafler, Howard L. Weiner
-
Patent number: 5571500Abstract: Disclosed herein is a method for treating autoimmune diseases in mammals by administration of one or more agents selected from the group consisting of autoantigens specific for the autoimmune disease, disease-suppressive fragments and analogs of said autoantigen in aerosol form.Type: GrantFiled: June 7, 1995Date of Patent: November 5, 1996Assignee: Autoimmune, Inc.Inventors: David A. Hafler, Howard L. Weiner
-
Patent number: 5569676Abstract: A method is described for alleviating the symptoms of non-rheumatoid arthritis by administering to the afflicted subject a therapeutically effective amount of cetyl myristoleate either orally, topically, or parenterally.Type: GrantFiled: May 24, 1995Date of Patent: October 29, 1996Inventor: Harry W. Diehl
-
Patent number: 5567409Abstract: A method and medical agents for the photodynamic diagnosis of rheumatoid arthritis of mammals, which agent comprises at least one member of fluorescent compounds selected from the group consisting of tetrapyrrole carboxylic acids having at least one carboxyl group, corresponding di- or tetrahydrotetrapyrrole carboxylic acids, and mono-, di- or polyamides of the tetrapyrrole carboxylic acids with amino-mono- or dicarboxylic acids and their salts.Type: GrantFiled: December 12, 1994Date of Patent: October 22, 1996Assignee: Nippon Petrochemicals Company, Ltd.Inventors: Katsuo Aizawa, Yukari Kuroiwa
-
Patent number: 5567590Abstract: Disclosed is a method for diagnosing inflammation in an animal which includes analyzing cells to assess glucocorticoid receptor binding affinity or glucocorticoid receptor number. A low binding affinity and high receptor number are each indicative of inflammation. Also disclosed is a method for treating inflammation in an animal, which inflammation causes glucocorticoid receptor alteration which includes suppressing the activity or expression of cytokines which, in the absence of suppression, alter glucocorticoid receptors. Also disclosed are methods for identifying Type II glucocorticoid receptor binding abnormality and for distinguishing Type I glucocorticoid receptor binding abnormalities from Type II. Further disclosed are treatments for steroid-resistant inflammatory disorders induced by IL-2 and IL-4 which are associated with glucocorticoid receptor binding abnormalities. The treatment includes administering an agent which is an IL-2 suppressor and/or an IL-4 suppressor.Type: GrantFiled: January 6, 1994Date of Patent: October 22, 1996Assignee: National Jewish Center for Immunology and RespiratoryInventors: Donald Y. M. Leung, Stanley J. Szefler, Joseph D. Spahn
-
Patent number: 5565441Abstract: Compounds useful in the treatment of inflammation structurally represented as Formula I ##STR1## one of X or Y is H and the other is selected from the group consisting of: ##STR2## or X and Y are taken together to form a ring selected from the group consisting of: ##STR3## as herein defined. The compounds are useful as anti-inflammatory and anti-arthritic agents.Type: GrantFiled: February 1, 1995Date of Patent: October 15, 1996Assignee: The Upjohn CompanyInventors: Richard A. Nugent, David J. Anderson, Stephen T. Schlachter
-
Patent number: 5565448Abstract: The present invention relates to the treatment and prevention of conditions wherein protein Kinase C inhibition is indicated.Type: GrantFiled: August 25, 1994Date of Patent: October 15, 1996Assignee: SmithKline Beecham CorporationInventors: Ponnal Nambi, Ashok D. Patil
-
Patent number: 5560935Abstract: The present invention provides a physiologically active substance which inhibits plasma kallikrein production, improves peripheral blood flow, and exhibits analgesic, antiinflammatory and antiallergic action. The physiologically active substance of the present invention is prepared by activating various animals or animal tissues by means of inoculation with virus or tumor cells which act as a stressor, and then extracting the effective factor from the activated tissues. The substance exhibits a pharmacological action of inhibiting activity for production of plasma kallikrein and recovering and normalizing abnormal functions which are associated with the diseased state. The physiologically active substance and pharmaceutical compositions of the present invention exhibit excellent regulating activity for biofunctions. They provide recovery and normalization of abnormal functions in living organisms in various diseased states.Type: GrantFiled: September 27, 1994Date of Patent: October 1, 1996Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Jin-emon Konishi, Giichi Hamada
-
Patent number: 5560913Abstract: The present invention relates to orally ingestible, pharmaceutical compositions containing at least one pharmaceutical active and a taste masking component.Type: GrantFiled: January 27, 1995Date of Patent: October 1, 1996Assignee: The Procter & Gamble CompanyInventor: Philip L. Kupper
-
Patent number: 5531992Abstract: A low molecular weight vegetable composition comprising a seed of Milk Thistle which are heated with far infrared rays, for example, using a vessel comprising ceramics and then brewed with brewing bacteria such as "Koji" fungus, digestive enzyme, protein hydrolase or a precursor giving said enzyme or said protein hydrolase.Type: GrantFiled: June 2, 1994Date of Patent: July 2, 1996Assignee: Kozo NiwaInventors: Hiroko Yamazaki, Masahiro Kuroda, Kozo Niwa
-
Patent number: 5529786Abstract: This invention provides a therapeutic pill comprising animal tissue containing a therapeutic amount of Type II collagen and a method of preparing animal tissue containing Type II collagen for treatment of Rheumatoid Arthritis in humans.Type: GrantFiled: February 28, 1994Date of Patent: June 25, 1996Inventor: Eugene R. Moore
-
Patent number: 5514704Abstract: A method of inhibiting leukotrienes comprising administering to a mammal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.3 is hydrogen, or a group of the formula ##STR2## wherein R.sub.4 is phenyl, substituted phenyl, naphthyl or substituted naphthyl, with the proviso that when R.sub.1 and R.sub.2 are both C.sub.1 -C.sub.6 alkyl, R.sub.3 is not hydrogen; and pharmaceutically acceptable salts thereof.Type: GrantFiled: March 13, 1995Date of Patent: May 7, 1996Assignee: Eli Lilly and CompanyInventors: Donald G. Carlson, George J. Cullinan, Kennan J. Fahey, William T. Jackson, Neal W. Roehm, Stephen M. Spaethe
-
Patent number: 5514703Abstract: A method of inhibiting 5-lipoxygenase comprising administering to a mammal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.3 is hydrogen, or a group of the formula ##STR2## wherein R.sub.4 phenyl, substituted phenyl, naphthyl or substituted naphthyl, with the proviso that when R.sub.1 and R.sub.2 are both C.sub.1 -C.sub.6 alkyl, R.sub.3 is not hydrogen; and pharmaceutically acceptable salts thereof.Type: GrantFiled: March 13, 1995Date of Patent: May 7, 1996Assignee: Eli Lilly and CompanyInventors: Donald G. Carlson, George J. Cullinan, Kennan J. Fahey, William T. Jackson, Neal W. Roehm, Stephen M. Spaethe
-
Patent number: 5506210Abstract: The invention relates to a method of anti-inflammatory and/or immunosuppressive treatment of an animal or human patient comprising administering to the patient an effective amount of at least one phosphosugar or derivative thereof, or a phosphosugar-containing oligosaccharide or polysaccharide or derivative thereof.Type: GrantFiled: December 29, 1992Date of Patent: April 9, 1996Assignee: The Australian National UniversityInventors: Christopher R. Parish, William B. Cowden, David O. Willenborg
-
Patent number: 5506224Abstract: N-acyl-derivatives of hydroxyamines suitable for the therapeutic treatment of pathologies characterized by degranulation of mast cells caused by a neurogenic and/or immunogenic hyperstimulation.Type: GrantFiled: November 8, 1993Date of Patent: April 9, 1996Assignee: Lifegroup S.P.A.Inventors: Francesco della Valle, Silvana Lorenzi, Jacobus C. J. J. Samson, Federica della Valle
-
Patent number: 5494668Abstract: A method of treating degenerative musculoskeletal diseases such as rheumatoid arthritis and osteoaarthritis in an animal, typically a human, comprises administering to the animal, typically enterally, in a convenient dosage form, a therapeutically effective amount of the beneficiated extracts of the plants ASHWAGANDHA (Withania somnifera), SALLAI GUGGUL (Boswellia serrata), TURMERIC (Curcuma longa), and GINGER (Zingiber officinale) in a predetermined proportion relative to each other with or without other biologically active inorganic ingredients, such as zinc sulphate. The beneficiated plant extracts are made in accordance with a novel process which is also disclosed.Type: GrantFiled: July 11, 1994Date of Patent: February 27, 1996Inventor: Bhushan Patwardhan
-
Patent number: 5486510Abstract: A mixture of .beta.-sitosterol glucoside and .beta.-sitosterol is administered to persons for the modulation or control of immune responses. The two compounds may be added in admixture or sequentially. Diseases such as viral and bacterial infections, autoimmune diseases, psoriasis, ezcema, asthma, cancer may be treated.Type: GrantFiled: November 8, 1993Date of Patent: January 23, 1996Assignee: Rooperol (NA) NVInventors: Patrick J. D. Bouic, Carl F. De Vosa Albrecht
-
Patent number: 5474987Abstract: The present invention relates to methods for the prevention and/or treatment of pathological processes involving the induction of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.Type: GrantFiled: February 3, 1995Date of Patent: December 12, 1995Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Ofer Lider, Rami Hershkoviz
-
Patent number: 5470857Abstract: This invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering an effective amount of a compound of the formula (1) ##STR1## wherein the hydroxy substituent on the cyclopentenyl ring is in the CIS configuration relative to the bicyclic substituent,Y.sub.3, Y.sub.7, Y.sub.8 and Y.sub.9 are each independently nitrogen or a CH group,Q is NH.sub.2, halogen or hydrogen, andZ is hydrogen, halogen, or NH.sub.2 ;or a pharmaceutically-acceptable salt thereof.Type: GrantFiled: November 8, 1994Date of Patent: November 28, 1995Assignee: Marion Merrell Dow Inc.Inventors: David R. Borcherding, Carl K. Edwards, III, Ronald E. Esser, Douglas L. Cole